BSE Live
Mar 13, 16:01Prev. Close
62.76
Open Price
61.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 13, 15:59Prev. Close
62.18
Open Price
61.01
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
58.17 (590)
| Cash Flow of Brooks Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 3.23 | 1.55 | -8.19 | 0.67 | -8.44 | |
| Net CashFlow From Operating Activities | 2.63 | -9.68 | 0.56 | 3.12 | -0.90 | |
| Net Cash Used In Investing Activities | -45.14 | 0.18 | -0.40 | 1.12 | -0.75 | |
| Net Cash Used From Financing Activities | 42.43 | 9.60 | -0.22 | -4.22 | 1.31 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -0.08 | 0.10 | -0.06 | 0.02 | -0.33 | |
| Cash And Cash Equivalents Begin of Year | 0.13 | 0.02 | 0.08 | 0.06 | 0.40 | |
| Cash And Cash Equivalents End Of Year | 0.04 | 0.13 | 0.02 | 0.08 | 0.06 |
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth